Triple-negative breast cancer continues to be labeled with a poor prognosis secondary to the fact that it tends to be more aggressive and poses a greater risk of recurrence. Because it lacks the receptors that many drugs have been designed to target, the standard of practice remains chemotherapy. Therefore, research has been focused on trying to identify other therapeutic targets for which agents already exist or are currently being developed. Within recent years, PD-L1 inhibition is being studied in trials as a new avenue for treatment options in these patients. Current evidence demonstrates increased benefit when using these agents in combination with chemotherapy.

As a result of the therapeutic advances and clinical research affecting the management of patients with breast cancer, clinicians can benefit by comparing their individual skills of diagnosis, treatment, and management of patients with their peers. This peer interaction is an integral part in enhancing clinical decision-making skills that can improve patient care.

With expanding treatment options, clinicians should understand important criteria used in selecting optimal first-and subsequent-line therapies for individuals with metastatic breast cancer. For clinicians, staying up to date with the available treatment options is important to integrate new evidence-based data into their clinical practice, and being familiar with the toxicity profiles is important to optimize patient outcomes.

With expanding treatment options, clinicians are challenged to understand important criteria used in selecting optimal first- and subsequent-line therapies for individuals with metastatic breast cancer. Staying up-to-date with the available treatment options is important to integrate new evidence-based data into their clinical practice, and being familiar with their toxicity profiles is important to optimize patient outcomes.

Few survivors meet all health behavior recommendations, and clinicians often report a lack of expertise, time, and resources to address healthy lifestyles with cancer survivors. Education on this topic can help clinicians encourage and support survivors to maintain and enhance their wellness.

Clinicians need to know what, when, and how to test and how to make subsequent informed, patient‐personalized treatment decisions. Accurate interpretation of results is critical; over-interpretation or misinterpretation will lead to treatment of patients with ineffective and expensive therapies, negatively impacting patient outcomes.

In order to define clinical situations that require appropriate locoregional therapies and use the right approach, clinicians need to stay up-to-date on the updates as well as the controversies.